帕利哌酮缓释片治疗急性期精神分裂症的疗效观察及对血清催乳素的影响

Clinical efficacy of paliperidone controlled release tablets and its influence on serum prolactin level in patients with acute schizophrenia

目的:探讨帕利哌酮缓释片治疗急性期精神分裂症患者的临床疗效、安全性及对血清催乳素水平的影响。方法:30例急性期精神分裂症患者,以帕利哌酮缓释片治疗8周。以阳性症状和阴性症状量表(PANSS)、社会功能量表(PSP)、Barnes静坐不能量表(BARS)、锥体外系副反应量表(SAS)及不自主运动量表(AIMS)分别于治疗前、治疗后4,8,15,28,57 d评定临床疗效、社会功能及不良反应;采用放射免疫法测定治疗前、治疗后28d、57d血清催乳素(PRL)水平。结果:23例患者完成8周的临床治疗,7例脱落。治疗后4,8,15,28,57d PANSS评分、PSP评分与治疗前相比均具有显著性差异(P<0.01),仅3例出现锥体外系反应,血清催乳素总体水平较入组前升高,但未见溢乳、闭经、男性乳房增大等症状。结论:帕利哌酮缓释片是一种临床疗效高、不良反应少的新型抗精神病药物,能升高患者的血清催乳素水平,但没有出现与催乳素相关的不良反应,为精神分裂症的治疗提供了一种新的有价值的选择。

Objective：To investigate the clinical efficacy of paliperidone and its influence on serum prolactin in patients with acute shizophrenia. Methods： Thirty acute schizophrenia patients were administrated with paliperidone controlled release tablets for 8 weeks. The curative effects, social function and adverse reactions were evaluated with the positive and negative syndrome scale （PANSS） , the Personal and Social Performance （PSP） scale, Barnes scale （BARS） , Extrapyramidal side effects scale（SAS） and involuntary movement scale（AIMS） before treatment and at day 4, 8, 15, 28 and 57 after administration. Serum prolactin level was measured with radioimmunity assay before treatment and at day 28 and 57. Results： 23 patients completed 8 weeks of treatment and 7 patients dropped out. Compared to the data before treatment, PANSS and PSP at day 4, 8, 15, 28 and 57 had obvious difference（P 〈 0.01 ）. Only 3 patients had extrapyramidal side effects during the treatment. The serum prolatin level was higher than that before treatment. No galactorrhea, menostasia and mastauxy were obtained in male patients. Conclusion： Paliperidone controlled release tablet is a new type antipsyehotie with high curative efficacy and less side effects. It can elevate the serum prolatin, but there is no prolaetin-related adverse reactions. Paliperidone controlled release tablet provides a valuable new treatment option for schizophrenia.